Share on StockTwits
 

Research analysts at JMP Securities boosted their price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from $68.00 to $110.00 in a report released on Friday, American Banking & Market News reports. JMP Securities’ price objective would suggest a potential upside of 31.48% from the stock’s previous close.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 7,890 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $85.75, for a total value of $676,567.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

ALNY has been the subject of a number of other recent research reports. Analysts at Deutsche Bank raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $108.00 in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note to investors on Tuesday, January 14th. They now have a $54.00 price target on the stock, down previously from $72.00. Finally, analysts at S&P Equity Research downgraded shares of Alnylam Pharmaceuticals to a “neutral” rating in a research note to investors on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $75.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 2.61% during mid-day trading on Friday, hitting $83.66. The stock had a trading volume of 461,655 shares. Alnylam Pharmaceuticals has a 52-week low of $21.60 and a 52-week high of $112.57. The stock’s 50-day moving average is $73.59 and its 200-day moving average is $59.50. The company’s market cap is $5.307 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 46.4% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals will post $-1.38 EPS for the current fiscal year.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.